NanoViricides is trading 6.99% higher at $1.44 on November 3, 2026, with no specific catalyst identified. - Searches found no company-specific announcement or reliable report directly explaining the move. - The latest identified company update, dated October 27, said its Ebola trial was progressing well; it predates this session. - Market context is mixed, and the biotech sector is reported lower, so neither clearly explains the gain.